08/29/23 8:30 AMNasdaq : PRLD conferenceslow floatPrelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberPrelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: Wells Fargo 18RHEA-AIneutral
08/03/23 8:00 AMNasdaq : PRLD earningslow floatPrelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdatePrelude TherapeuticsRHEA-AIneutral
05/31/23 8:30 AMNasdaq : PRLD conferenceslow floatPrelude Therapeutics To Participate in Jefferies Healthcare ConferencePrelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Jefferies Healthcare Conference, taking place in New York City, June 7 to 9, 2023.RHEA-AIneutral
05/18/23 7:00 AMNasdaq : PRLD offeringlow floatPrelude Therapeutics Announces Pricing of Public OfferingPrelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its underwritten public offering of 3,048,522 shares of its voting common stock andRHEA-AIneutral
05/17/23 4:08 PMNasdaq : PRLD offeringlow floatPrelude Therapeutics Announces Launch of Proposed Public OfferingPrelude Therapeutics Incorporated (“Prelude” or the “Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced an underwritten public offering of $100.0 million of shares of common stock and, inRHEA-AIneutral
05/08/23 8:30 AMNasdaq : PRLD earningslow floatPrelude Therapeutics Announces First Quarter 2023 Financial Results and Operations UpdatePrelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncologyRHEA-AIneutral
04/27/23 8:30 AMNasdaq : PRLD conferenceslow floatPrelude Therapeutics to Participate in Three Healthcare Investor Conferences in MayPrelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: H. C.RHEA-AIneutral
04/11/23 8:30 AMNasdaq : PRLD conferenceslow floatPrelude Therapeutics to Present at American Association for Cancer Research 2023 ConferencePrelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight abstracts being presented at theRHEA-AIneutral
03/15/23 8:30 AMNasdaq : PRLD earningslow floatPrelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate UpdateFour differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchangedRHEA-AIpositive
03/15/23 8:00 AMNasdaq : PRLD clinical triallow floatPrelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic CancersPrelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, inRHEA-AIneutral